Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision
Journal for ImmunoTherapy of Cancer · 2024-06 · 12 (6) · e009063
DOI: 10.1136/jitc-2024-009063 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 19.06.2024. Verfasst von Leisha A Emens und 10 weiteren Autor:innen. Beteiligte Einrichtung: Ankyra Therapeutics, Cambridge, Massachusetts, USA emensle@icloud.com jwargo@mdanderson.org. Hauptthemen laut MEDLINE: Immunotherapy, Neoplasms. Die Arbeit wurde bisher 173-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Cancer immunotherapy has flourished over the last 10–15 years, transforming the practice of oncology and providing long-term clinical benefit to some patients. During this time, three distinct classes of immune checkpoint inhibitors, chimeric antigen receptor-T cell therapies specific for two targets, and two distinct classes of bispecific T cell engagers, a vaccine, and an oncolytic virus have joined cytokines as a standard of cancer care. At the same time, scientific progress has delivered vast amounts of new knowledge. For example, advances in technologies such as single-cell sequencing and spatial transcriptomics have provided deep insights into the immunobiology of the tumor microenvironment. With this rapid clinical and scientific progress, the field of cancer immunotherapy is currently at a critical inflection point, with potential for exponential growth over the next decade. Recognizing this, the Society for Immunotherapy of Cancer convened a diverse group of experts in cancer immunotherapy representing academia, the pharmaceutical and biotechnology industries, patient advocacy, and the regulatory community to identify current opportunities and challenges with the goal of prioritizing areas with the highest potential for clinical impact. The consensus group identified seven high-priority areas of current opportunity for the field: mechanisms of antitumor activity and toxicity; mechanisms of drug resistance; biomarkers and biospecimens; unique aspects of novel therapeutics; host and environmental interactions; premalignant immunity, immune interception, and immunoprevention; and clinical trial design, endpoints, and conduct. Additionally, potential roadblocks to progress were discussed, and several topics were identified as cross-cutting tools for optimization, each with potential to impact multiple scientific priority areas. These cross-cutting tools include preclinical models, data curation and sharing, biopsies and biospecimens, diversification of funding sources, definitions and standards, and patient engagement. Finally, three key guiding principles were identified that will both optimize and maximize progress in the field. These include engaging the patient community; cultivating diversity, equity, inclusion, and accessibility; and leveraging the power of artificial intelligence to accelerate progress. Here, we present the outcomes of these discussions as a strategic vision to galvanize the field for the next decade of exponential progress in cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Ankyra Therapeutics, Cambridge, Massachusetts, USA emensle@icloud.com jwargo@mdanderson.org.
- Novigenix, Epalinges, Switzerland.
- The Gene Lay Institute of Immunology and Inflammation, Ann Romney Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Department of Immunology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Department of Pediatrics and Carbone Cancer Center, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, USA.
- Patient Advocates in Research (PAIR), Danville, California, USA.
ORCID-Profile: Leisha A Emens, Ana Carrizosa Anderson, Christian M Capitini, James L Gulley, Patrick Hwu, Avery D Posey, Ann W Silk
Zitieren
APA
Emens, L. A., Romero, P. J., Anderson, A. C., Bruno, T. C., Capitini, C. M., Collyar, D., Gulley, J. L., Hwu, P., Posey, A. D., Silk, A. W., & Wargo, J. A. (2024). Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision. Journal for ImmunoTherapy of Cancer, 12(6), e009063. https://doi.org/10.1136/jitc-2024-009063
Vancouver
Emens LA, Romero PJ, Anderson AC, Bruno TC, Capitini CM, Collyar D, et al. Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision. Journal for ImmunoTherapy of Cancer. 2024;12(6):e009063. doi:10.1136/jitc-2024-009063
BibTeX
@article{Emens2024,
author = {Emens, Leisha A and Romero, Pedro J and Anderson, Ana Carrizosa and Bruno, Tullia C and Capitini, Christian M and Collyar, Deborah and Gulley, James L and Hwu, Patrick and Posey, Avery D and Silk, Ann W and Wargo, Jennifer A},
title = {Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
volume = {12},
number = {6},
pages = {e009063},
doi = {10.1136/jitc-2024-009063}
}
EUVIMED